<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994263</url>
  </required_header>
  <id_info>
    <org_study_id>MT-09</org_study_id>
    <nct_id>NCT03994263</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI</brief_title>
  <official_title>A Pilot and Prospective Study to Observe the Mechanism of Action of Medi-Tate i-Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) With Magnetic Resonance Imaging (MRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medi-Tate Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medi-Tate Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study
      designed to observe the mechanism of action of iTind when using MRI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective:

      To validate the iTind efficacy by using MRI in subjects with symptomatic BPH. Specifically
      the pressure points created by the iTind's struts and its implications on blood flow to the
      prostate will be assessed.

      Efficacy Endpoints:

      The endpoints of this study are:

        -  Decrease in transition zone volume

        -  Monitor size and location of ablative lesions

        -  Monitor change in time of lesions

        -  Monitor the correspondence change in prostate tissue All the above will be assessed by
           using MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE rate</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of device related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unexpected SAE</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of unexpected serious adverse events deemed as related to Meditate iTIND and/or to implantation/retrieval procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device complications</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of Meditate iTIND and/or to implantation/retrieval procedures complications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>iTind arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITind device implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ITind device implant</intervention_name>
    <description>device implanted for 5-7 days</description>
    <arm_group_label>iTind arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject signed informed consent form (ICF)

          -  Age 40 and above- Male with symptomatic BPH.

          -  IPSS symptom severity score ≥ 13

          -  Peak urinary flow of &lt; 12 ml/sec

          -  Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)

          -  Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal
             values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks
             prior of device implantation)

          -  Subject able to comply with the study protocol

          -  Normal urinalysis and negative urine culture

          -  Subjects that are able to undergo MRI.

        Exclusion Criteria:

          -  A post void residual (PVR) volume &gt; 250 ml measured by ultrasound or acute urinary
             retention

          -  Confirmed or suspected bladder cancer;

          -  Recent (within 3 months) cystolithiasis or hematuria;

          -  Urethral strictures, bladder neck contracture, urinary bladder stones or other
             potentially confounding bladder pathology;

          -  An active urinary tract infection.

          -  Enrolled in another treatment trial for any disease within the past 30 days.

          -  Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal
             disease if the therapy may potentially cause injury to sites of previous rectal
             surgery, e.g., if a transrectal probe is used;

          -  Previous pelvic irradiation, cryosurgery or radical pelvic surgery;

          -  Previous prostate surgery, balloon dilatation, stent implantation, laser
             prostatectomy, hyperthermia, or any other invasive treatment to the prostate

          -  Median lobe obstruction of the prostate (larger than 1cm).

          -  Cancer that is not considered cured, except basal cell or squamous cell carcinoma of
             the skin (cured defined as no evidence of cancer within the past 5 years)

          -  Patient with renal dysfunction

          -  Any serious medical condition likely to impede successful completion of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male with symptomatic BPH</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bschleipfer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weiden Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Bschleipfer, Prof.</last_name>
    <phone>01727716627</phone>
    <email>Th.B@gmx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG Klinik für Urologie, Kinderurologie und interdisziplinäres Prostatakarzinomzentrum</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bschleipfer Bschleipfer</last_name>
      <email>Th.B@gmx.de</email>
    </contact>
    <contact_backup>
      <last_name>Irene Baunoch</last_name>
      <phone>+499613033307</phone>
      <email>irene.baunoch@kliniken-nordoberpfalz.ag</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

